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Abstract
To determine the role of striatal dopaminergic innervation on upper limb synergies during walking, we measured arm
kinematics in 13 subjects with Parkinson disease. Patients were recruited according to several inclusion criteria to represent
the best possible in vivo model of dopaminergic denervation. Of relevance, we included only subjects with normal spatio-
temporal parameters of the stride and gait speed to avoid an impairment of upper limbs locomotor synergies as a
consequence of gait impairment per se. Dopaminergic innervation of the striatum was measured by FP-CIT and SPECT. All
patients showed a reduction of gait-associated arms movement. No linear correlation was found between arm ROM
reduction and contralateral dopaminergic putaminal innervation loss. Still, a partition analysis revealed a 80% chance of
reduced arm ROM when putaminal dopamine content loss was .47%. A significant correlation was described between the
asymmetry indices of the swinging of the two arms and dopaminergic striatal innervation. When arm ROM was reduced, we
found a positive correlation between upper-lower limb phase shift modulation (at different gait velocities) and striatal
dopaminergic innervation. These findings are preliminary evidence that dopaminergic striatal tone plays a modulatory role
in upper-limb locomotor synergies and upper-lower limb coupling while walking at different velocities.
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Introduction
Upper limb locomotor synergies are a basic component of
human gait. They represent an active phenomenon driven by
locomotor centers within spinal cord and the brainstem and
modulated by cortical and subcortical inputs [1,2]. Information on
neural control of locomotor automatism and gait-related arm
motion in humans is still scanty. Animal studies, as well as
preliminary functional imaging studies in humans, indicate that
locomotor movements are coordinated by spinal networks referred
to as a central pattern generators (CPGs), which are governed by
the brainstem locomotor command region that, in turn, is under
the control of the basal ganglia and premotor cortex [3–9].
Parkinson disease (PD) is a progressive neurological condition
characterized by bradykinesia, rigidity, postural instability and
possibly tremor. Patients with PD typically show little or no arm
oscillation while walking, and this is often the first clinical motor
sign to appear [10,11]. In PD patients, the arm swing is not
correlated with clinically tested shoulder rigidity [10] and often
disproportional to the degree of upper limb akinesia during
voluntary alternating movements, thus pointing to a task-specific
motor disturbance associated with walking. At an anatomopatho-
logical level, PD is mainly characterized by the loss of
dopaminergic neurons in the substantia nigra pars compacta,
which leads to striatal dopamine depletion [12]. It has been
estimated that motor PD symptoms appear when the loss of
dopamine neurons reaches the 50% to 60% threshold, [13] which
corresponds to a 70% to 80% decrease in putaminal dopamine
content [14].
The aim of this study is to investigate a putative role of
dopamine and the striatum in locomotor upper limb automatism,
taking into account their relationship with walking speed. Patients
were carefully selected to represent a clinically homogenous in vivo
model of dopaminergic striatal innervation loss (see, Subjects) which
was measured by [123I] N-v-fluoropropyl-2b-carbomethoxy-3b-
(4-iodophenyl) tropane (FP-CIT) and single-photon computed
tomography (SPECT).
Materials and Methods
Ethics Statement
The local institutional review board (Section of Human
Physiology, DePT) approved the study and all patients provided
written informed consent.
Subjects
We tested 13 subjects with idiopathic PD (six males; mean age:
64 years; range: 52–73 years; disease duration mean: 5 years;
range: 3–6) and a control group (HC) of 10 neurologically healthy
adults (seven males; mean age: 64 years; age range: 55–70 years).
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The diagnosis of PD was made according to the UK Parkinson
Disease Brain Bank criteria and patients were clinically evaluated
by means of the Unified Parkinson Disease Rating Scale motor
part (UPDRS-III; range: 0–108). Median UPDRS-III score was 21
(range: 11–32). A sub-score for unilateral arm rigidity and
bradykinesia (UPDRSrb) was calculated as the sum of UPDRS
items 22 (rigidity), 23 (finger taps), 24 (hand movements), 25 (rapid
alternating movements of hands). Median UPDRSrb score of the
worst arm was 8 (range: 4–11) and of the less affected arm was 4
(range: 1–5). We selected only mildly affected patients for this
study (Hoehn & Yahr II) (see later).
At the time of the study, and during a follow-up time of at least
six months after enrollment, no patient showed any signs
indicative for atypical parkinsonism (e.g. gaze abnormalities,
autonomic dysfunction, psychiatric disturbances, etc.). All patients
reported a marked improvement (.30% UPDRS-III score
reduction) after the intake of L-Dopa or dopamine agonists. L-
Dopa daily dose and L-Dopa Equivalent Daily Doses (LEDDs)
were also recorded, with the latter calculated according to the
following conversion ratio: 100 mg levodopa = 1.5 mg pramipex-
ole = 6 mg ropinirole. Median value of LEDDs per day was
500 mg (range 200–625 mg).
All subjects were screened for cognitive impairment by the
Mini-Mental State examination, Clock Drawing Test and Frontal
Assessment Battery and excluded if not meeting normal, age-
related performance.
Other exclusion criteria for study participation were a history of
neurological disorders (other than PD for patients), head trauma
with loss of consciousness, orthopedic diseases, systemic illness or
previous orthopedic, brain or spinal cord surgery. A MRI was
performed within six months from enrollment and only subjects
with normal results (i.e., no sign of white matter lesion or atrophy)
participated in the study.
Gait disturbance is a key component of motor disability of PD
and patients may variably present with reduced gait speed,
shortened stride length, prolonged stance and double support
phases [15]. At an early disease stage, PD patients may still show
normal spatio-temporal gait parameters during steady linear
walking [16]. To avoid an impairment of upper limbs locomotor
synergies as a consequence of gait impairment per se, we enrolled
only PD patients with normal spatio-temporal parameters of the
stride (Table 1).
Experimental Protocol and Data Processing
After a 3-day washout of antiparkinsonian medication, subjects
performed three sets of six walking trials, at a self-chosen
‘‘preferred’’ speed, ‘‘slow’’ and ‘‘fast’’ speed, in random order
along a 10 m path, following verbal instruction in the absence of
external feedback. Set-up and data processing has been extensively
described elsewhere [16,17]. In brief, kinematics of body segments
were measured during walking, using an optoelectronic system
(SMART, BTS, Milan, Italy, sampling frequency 60 frames/s),
which computed the 3D coordinates of spherical markers (15 mm
diameter) attached on bony fixed landmarks. The marker
coordinates were low-pass filtered (cut-off frequency 3–7 Hz,
self-estimated by a linear-phase autoregressive model-based
derivative assessment algorithm). Specific sets of parameters for
the characterization of each task were automatically extracted by
ad hoc algorithms and then visually inspected to check for possible
errors. In particular, the time course of the angular displacement
of the humerus segment of the arm with respect to the vertical
(positive forward) [17] were computed in planes perpendicular to
the inter-acromion line. These measures allowed to analyze the
pendular behavior of the arm segment independently from
shoulder and pelvic girdle horizontal rotation associated with
trunk torsion. Angular profiles were normalized in time as a
percentage of the stride duration, and for each cycle we extracted
the range of motion (ROM) of absolute arm angle. Finally, arm
swing asymmetry (ASA) was calculated according to Zifchock and
coll. [18] as follows: ASA = (45u-arctan(ArmSwingLEFT/ArmS-
wingRIGHT))*100/90u.
For arm ROM larger than 3u, the phase-shift (upper-lower limb)
was further computed as the temporal delay between the positive
peak (antero-posterior swing) of the wrist and the negative peak of
malleolus, between 20% and 80% of the stride cycle. When the
upper limb produced two oscillations per stride, which may occur
at the lower walking speeds, phase-shifts were computed using the
first positive peak of arm oscillation.
For each subject all variables (e.g. gait speed, arm ROM, phase-
shift, etc.) were averaged over trials.
To characterize the speed-related effects, the slopes of the
regression lines of arm ROM, phase-shift as well as of spatio-
temporal parameters of the stride were computed for each subject
as a function of the gait speed.
SPECT Data Acquisition, Processing and Analysis
Dopamine-transporter (DAT) values were measured by means
of Single Photon Computed Tomography (SPECT) with [123I] N-
v-fluoropropyl-2b-carbomethoxy-3b-(4-iodophenyl) tropane (FP-
CIT).
SPECT data acquisition and reconstruction has been described
in details elsewhere [19]. In brief, intravenous administration of
110–140 MBq of FP-CIT (DaTSCAN, GE-Healthcare, UK) was
performed 30–40 minutes after thyroid blockade (10–15 mg of
Lugol oral solution) in PD patients subsequently overnight
withdrawal of dopaminergic therapy. Data were compared with
a group of 15 healthy subjects (four males; mean age, 62; age
range: 44–70 years).
Brain SPECT was performed by means of a dedicated triple
detector gamma-camera (Prism 3000, Philips, Eindhoven, the
Netherlands) equipped with low-energy ultra-high resolution fan
beam collimators (4 subsets of acquisitions, matrix size 1286128,
radius of rotation 12.9–13.9 cm, continuous rotation, angular
sampling: 3 degree, duration: 28 minutes).
Brain sections were reconstructed with an iterative algorithm
(OSEM, 4 iterations and 15 subsets) and then processed by 3D
filtering (Butterworth, order 5, cut-off 0.31 pixel-1) and attenua-
tion correction (Chang method, factor 0.12).
FP-CIT uptake values for the caudate nucleus and putamen of
both PD patients and healthy subjects were calculated according
to Basal Ganglia Matching Tool [20].
Striatal uptake values were used to calculate an asymmetry
index (AI), as follows: AI = (VOILEFT – VOIRIGHT)/(VOILEFT+-
VOIRIGHT)*200.
General Statistical Analysis
Distribution was non-normal for most of the variables, as
assessed by Shapiro-Wilk’s test. Accordingly, descriptive statistics
and comparisons were always based on median/range values and
non-parametric tests, respectively.
ChiSquare was used to test demographic homogeneity among
groups regarding gender.
To relate comparisons to DAT binding values, upper and lower
limbs were also re-classified into ipsilateral and contralateral
according to the putamen with greater dopaminergic innervation
loss. For healthy controls, left hemibody refers conventionally to
ipsilateral.
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Differences in spatio-temporal gait parameters, arm ROM,
phase shifts indexes and slope parameters between control and
patient groups were analyzed by means of Wilcoxon two-sample
test.
To quantify the (in)consistency of these measures and the stride-
to-stride variability, we calculated the coefficient of variation (CV)
of these measures when walking at preferred gait speed.
When comparing two hemibodies of the same subject (both for
kinematic as well as DAT binding values) we applied a Wilcoxon
matched pair test.
Hoeffding’s D measure was used to identify correlations among
DAT binding values and biomechanic data (including asymmetry
indexes) that differed among patients and healthy controls. If no
linear correlation was found, we applied partition analyses in
search for a DAT binding cut-off value related to abnormal
kinematic parameters.
Statistical analyses were performed with the JMP statistical
package, version 8.0.2 (SAS Institute, Inc., Cary, NC, USA).
Results
No difference was found among PD patients and HC for gender
distribution and age.
Imaging Findings
In comparison to HC, patients showed reduced DAT binding
values in the putamen (PD, right median: 2.19; right range: 1.2–
3.51; left median: 2.63, left range: 1.41–3.4; HC, right median:
4.94, right range: 3.07–5.71; left median: 4.94, left range: 2.96–
5.71; p,0.01 all) and caudate nucleus (PD, right median: 4.06;
right range: 2.74–5.49; left median: 4.17, left range: 2.3–4.94; HC,
right median 5.16, right range: 3.18–6.48; left median: 5.05, left
range: 3.07–6.7; p,0.05 all) thus further supporting the clinical
diagnosis of PD. In HC, no difference was described when
comparing DAT binding values of right and left hemisphere. In
PD patients, DAT binding values of the most affected putamen
(median: 1.97; range: 1.2–3.07) were on average 30% lower than
in the opposite hemisphere (median: 2.85; range: 1.86–3.51;
p,0.01). No statistical difference was instead found when
comparing DAT binding values of the caudate nucleus of PD
patients (most affected, median: 3.73; range: 2.3–4.83; less
affected, median: 4.2; range: 2.74–5.5). Average AI value for the
putamen of PD patients was 30 (range 6–59); all HC had a
putamen AI score below 5 (putamen AI score average 2.1; range
0–4).
UPDRSrb score was negatively correlated with striatal DAT
binding values (p = 0.01, RSquare = 0.20), but this relationship
explained only 20% of the variance. This finding is in agreement
with previous results of SPECT and FP-CIT in subjects with PD
and confirms the validity of the methods applied in this study [21].
Walking at Preferred Speed
As expected, no difference was found for lower limbs spatio-
temporal gait parameters (i.e. stride length, stride time and stance)
between patients and controls at preferred gait speed (see, Subject).
In HC, right and left hemibodies did not show any difference for
any gait-related parameters (Table 1).
Consistency of the spatio-temporal measures did not differ
significantly between the patient and control group.
When arms were re-classified into ipsilateral and contralateral
to the more dopamine depleted hemisphere (see, General
statistical analysis), the contralateral arm ROM of PD patients
Table 1. Spatio-temporal parameters of the stride, arm ROM and phase shift of subjects with Parkinson disease and healthy
subjects.
Parkinson patients Healthy subjects
Gait speed (Km/h) 3.81 (1.86, 7.81) (preferred gait speed range: 2.87, 4.35) 3.82 (1.24, 9.94) (preferred gait speed range: 3.35, 4.4)
Contralateral Ipsilateral Contralateral (Right) Ipsilateral (Left)
Arm ROM (u) 7.48 (1.47, 32.06)** 18.19 (2.11, 29.8)** 25.27 (2.29, 31.8) 25.71 (5.21, 38,15)
Phase shift (%stride) 215.35 (223.1, 25.6)* 211.8 (216.9, 26.1) 210.17 (219.1, 25.4) 29.97 (218.9, 23.5)
Stride length (mm/BH) 0.68 (0.55, 0.28) 0.68 (0.49, 0.82) 0.7 (0.57, 0.82) 0.69 (0.54, 0.81)
Stride time (sec) 0.89 (0.73, 1.47) 0.92 (0.75, 1.42) 0.86 (0.8, 1,28) 0.87 (0.64, 1.28)
Stance (%stride) 65.2 (58.78, 71.25) 66.56 (62.77, 72.84) 64.42 (61.76, 72.6) 64.28 (61.54, 81.82)
Slope arm ROM
[u/(km h21)]
2.08 (0.12, 6.68) 3.47 (0.43, 7.82) 3.96 (2.1126.34) 3.5 (1.2426.58)
Slope phase shift
[%stride/(km h21)]
4.98 (2.9, 11.6)* 3.85 (2.52, 9.6)* 3.04 (1.5524.68) 2.88 (1.824.16)
Slope stride length
[mm/BH/(km h21)]
0.07 (0.05, 0.09) 0.08 (0.05, 0.09) 0.06 (0.0520.08) 0.07 (0.0520.08)
Slope stride time
[sec/(km h21)]
20.18 (20.3, 20.12) 20.17(20.3, 20.11) 20.16 (20.22, 20.09) 20.16 (20.23, 20.09)
Slope stance
[%stride/(km h21)]
20.18 (20.29, 20.12) 22.0 (23.7, 21.4) 20.15 (20.22, 20.1) 21.86 (22.55, 21.23)
Median values, non-outlier min-max, and levels of statistical difference (Mann-Whitney U-test or Matched pairs) are reported. Data refer at walking at different velocities
unless otherwise specified.
*p,0.05 (PD vs. HC); ** p,0.01 (PD vs. HC). BH= body height (mm). ROM= range of motion; Phase shift = temporal delay (%stride) between the positive peak (antero-
posterior swing) of the wrist and the negative peak of malleolus; Stride = the period from initial contact of one foot and following initial contact of the same foot, is one
gait cycle. Stance =gait phase when a foot is in contact with the ground, it begins with initial heel contact and ends with toe off.
For Parkinson patients, ipsilateral and contralateral refers to the more dopamine depleted hemisphere. For healthy controls, left hemibody refers conventionally to
ipsilateral.
doi:10.1371/journal.pone.0051464.t001
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was reduced when compared to the ipsilateral one (trend towards
significance, p = 0.07; Table 1). Contralateral arms also showed a
significant anticipation of maximum arm flexion (forward move-
ment) in relation to ipsilateral thigh extension (backward
movement), compared to controls (Table 1).
Of relevance, only four subjects with PD showed reduced arm
ROM bilaterally. The remaining nine patients had one arm with
ROM in the range of normality (ROM.18u [mean ROMHC-1SD
ROMHC]). In the latter group of patients, all but two arms with
reduced ROM were contralateral to the putamen with lower DAT
binding values. Still, the putamen corresponding to the arm with
ROM in the range of normality had over 45% DAT binding loss
(with respect to the median value of our normal subjects).
No linear correlation was found between arm ROM reduction
and dopaminergic innervation loss. A partition analysis revealed a
80% chance of reduced arm ROM when putaminal DAT binding
value was below 2.63 (.47% reduction with respect to median
value of normal subjects).
Average ASA value was 29 (range: 18–35) for PD and 6 for HC
(range: 4–12). ASA and AI indices of both the caudate nucleus
(p = 0.005, RSquare = 0.52) and the putamen (Figure 1; p = 0.001;
RSquare = 0.62) were strongly correlated. This correlation proved
to be statistically significant also when weighted for UPDRSrb and
UPDRS-III scores. Last, no correlation was found between
UPDRSrb and UPDRS-III scores and arm ROM.
Walking at Different Speeds
When walking at different velocities, the range of speeds was
comparable across subjects and PD patients and large enough to
reliably compute a slope line.
No difference was found for lower limbs spatio-temporal gait
parameters (i.e. stride length, stride time and stance) between
patients and controls also when walking at different gait velocities.
Phase shift modulation (slope) was significantly higher in PD
patients than controls (p,0.05, Table 1). All patients were able to
normally modulate all other spatio-temporal gait parameters and
arm ROM (both ipsilateral and contralateral) when walking at
different velocities (Table 1). Interestingly, patients with reduced
arm ROM (,18u) when walking at preferred gait speed showed a
significantly higher capability of modulating upper-lower limb
phase shift which positively correlated with the corresponding
dopaminergic content of the putamen (RSquare = 0.37, p = 0.01)
and caudate nucleus (RSquare = 0.38, p = 0.01). This correlation
was not present if arm ROM was in the range of normality when
walking at preferred gait speed (Figure 2A and B).
Discussion
Some relevant conclusion can be drawn from the present study:
(1.) We confirmed that early-stage PD patients may exhibit normal
spatio-temporal gait parameters [16]. The presence of normal
lower limb locomotor automatisms in subjects with reduced arm
ROM supports the notion that both types of movement may be
differentially organized [17].
(2.) We did not find a linear correlation between arm ROM
reduction and corresponding putaminal dopaminergic depletion.
Rather, we were able to define a cut-off value for dopaminergic
putaminal innervation loss before arm ROM would decrease. (3.)
Inter-limb synergies might be influenced by the imbalance of
dopaminergic striatal tone between the two hemispheres as
shown by the strong correlation between ASA and AI indexes.
These findings question a prominent unihemispheric control of
arm swing during walking. Still, the ASA index should be
carefully interpreted as possibly related to the cut-off itself.
Indeed, in all but two patients with arm ROM unilaterally
reduced, the arm with reduced ROM (according to our
reference value of 18u) was contralateral to the putamen with
Figure 1. ASA significantly correlated to the AI of DAT binding values of the putamen (see, Methods).
doi:10.1371/journal.pone.0051464.g001
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greater dopaminergic innervation loss. (4.) When walking at
different gait velocities, arms with reduced ROM showed an
upper-lower limb coupling (phase shift) influenced by putaminal
dopaminergic innervation. (5.) Locomotor synergies were inde-
pendent of the lateralization of akinetic-rigid symptoms. Such a
discrepancy may provide preliminary evidence for a different
central organization of these entities in PD patients. Indeed,
bradykinesia and rigidity are mainly related to the thalamo-
cortical-basal ganglia loop with strict lateralized organization.
[21,22] Conversely, limbs coordination, especially during auto-
matically performed motor task, may be related to inter-
hemispheric projections of basal ganglia and possibly involve
also mesencephalic centers such as the pedunculopontine
nucleus (PPN) and the reticular system [23].
Limitations in our study must be considered. We arbitrarily
excluded patients with abnormal spatio-temporal parameters at
lower limbs to possibly avoid upper limbs related changes. By
doing this, we limited the patient sample and neglected well
known PD-related gait disturbances, including abnormal timing
of gait and stride-to-stride variability [24]. Another limit of this
study is that PD patients were not drug-naı¨ve. Still, the 3-day
wash-out as well as the several inclusion criteria support the
assumption that the enrolled PD patients well represent an in vivo
model of dopaminergic deficit and allowed us to selectively
investigate the role of intrinsic dopamine and the striatum in
upper limbs locomotor synergies. Last, we cannot exclude in this
study a direct role of a dopaminergic spinal innervation
originating from the dorsal posterior hypothalamus (A11 region)
on locomotor-related movements. Beside local hypothalamic
connections, projections to the neocortex and to the serotonergic
dorsal raphe, A11 neurons descend as the sole source of spinal
dopamine mainly through the dorsolateral funiculus [25] and
innervate most heavily the superficial sensory-related dorsal horn
and the intermediolateral nucleus [26]. A loss of A11 neurons
might eventually alter a possible interplay between dopamine and
serotonin at a spinal level and result in loss of modulation during
locomotion-like activity [27]. The role of the A11 neurons in the
pathophysiology of PD and in locomotion in general, has not
been explicitly tested.
From a anatomo-physiological perspective, the gait-related
pendular motion of upper extremities is a subconsciously and
automatically performed motor task. Inter-limb coordination
remains stable despite changes of limb segment mass, suggesting
independence from peripheral mechanism [28] and it is
maintained across kinematically and kinetically different tasks,
thus possibly related to a common neural control [29].
Descending pathways responsible for the control of locomotor
limb movements, can be ascribed to direct cortical-motoneuronal
input and indirect pathways of the basal ganglia [30,31,32].
Preliminary evidence suggest that dopaminergic neurons play an
important role in the execution of self-determined movements
[33], in the automatic nature of the rhythmic bilateral movements
of the lower-limbs [34] and the persistence of gait execution [9].
This study provides additional information to disentangle a
putative role of dopamine and the striatum in locomotor synergies.
We suggest an interhemispheric rather than unihemispheric
influence on inter-limb coupling. This may be particularly evident
when dopaminergic striatal innervation is greatly reduced (.47%
dopaminergic putaminal innervation loss). Furthermore, when
arm ROM is reduced, the modulation of upper-lower limb
coupling (phase shift) is also related to dopaminergic striatal
content.
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